3 startups working in the space: 1) Unlearn.AI - using digital twins for control arms 2) Owkin - ‘counterfactual outcomes’ to develop patient profiles essentially 3) Power - increasing patient awareness & matching to enrolling clinical trials

This is bad news... and requires a change in strategy... starting with working with communities - and addressing barriers and creating benefits. "U.S. clinical trial diversity dropped to its lowest level of the decade, according to IQVIA US report “Global Trends in R&D 2023.”"

Congrats to our friends Aicuris. We’re rooting for you! Promising results and a new clinical trial has been announced. herpescureadvocacy.com/2023/03/29/pro…

Excited to be involved in my first clinical trial

My neighbor has stage 4 cancer. He's been on chemo for 14 months (yes, it's true), and now he's doing a clinical trial. He still works 2 jobs. Still does his yard work. What a fucking inspiration he is to me, and I'll throw the biggest party when he kicks it's ass.

Attending #ASCO2023 as a survivor, patient advocate, and witness to my family's battles against cancer will be an emotional journey. Now it is also my life’s work in building a company to helping people access the most promising clinical trials #ClinicalTrials Power

Congratulations to CRV backed founders Bask ⚡️ and Brandon 🎉 of Power for making this year’s Forbes Under 30. forbes.com/30-under-30/20… #CRVVC #PowerToThePatient #ForbesUnder30

Sites don’t want more leads, they want qualified ones At Power, we focus on quality > quantity using: 📋 Enriched profiles using EMRs 💊 Full Rx history 🩺 Comorbidity checks 🗺️ Site-specific geo filters Why? Better referrals = faster enrollment linkedin.com/pulse/powers-q…

We recently examined the impact of our Recruitment Management Platform for Sites. Turns out, CRCs who use our direct messaging inbox with patients book screening visits at an 8x higher rate. Read more on Brandon 🎉's newsletter, Clinoops, here: linkedin.com/pulse/grow-scr…

🧠 dan karlin, CMO of MindMed, joined us to talk about their new approach to anxiety care using pharmaceutical-grade psychedelics and phase 2 results for Generalized Anxiety Disorder Links to listen to episode: withpower.com/hub/podcast/ps…

Too many trials are delayed because recruitment planning came too late. Our white paper last year shares how top sponsors are modernizing patient recruitment—from ROI to data-driven recruitment planning 📘 Read the Blueprint: withpower.com/hub/resources/…

💬 “With regular psilocybin, you might be waiting an hour... with our deuterated psilocin, we see effects in about 15 minutes.” -Doug Drysdale, CEO of CybinInc modified psychedelics could lead to faster, scalable treatments 🎧 withpower.com/hub/podcast/go…

Missed it? Last Patient In, Power’s resource hub on neuropsychiatry & neurodegeneration is live. Find white papers, top sites for CNS recruitement, interviews with CNS leaders & more, all in one place. Subscribe for updates: withpower.com/hub

Want the shirt?👉forms.gle/FkQJRYxHLH5WxD… Our controversial t shirts were such a hit at DPHARM last year that we're bringing them back :)

“Patients won’t share their medical records.” That’s often the assumption. But 70%+ of patients do with Power because trust is built into the process. It’s not if patients will engage, it’s how you ask. Read more here: linkedin.com/pulse/how-we-b…

🧠Our podcast with Jeff Winton, Founder of Rural Minds, on tackling the mental health crisis in rural America. Listen here: withpower.com/hub/podcast/th…

We are co-hosting the CNS Summit community event in San Francisco on our rooftop. Check out all details below! Sign up form here: lnkd.in/gfsg4JSq

How do you progress a psychedelic-based treatment through development and onto patients in need? Cosmo Feilding Mellen, CEO of Beckley Psytech, on the future of psychedelic medicine. 🎧 Listen here: withpower.com/hub/podcast/wh…